Diovan
-
{
- All
- News
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
-
Lupin Launches Generic Diovan Tablets in US
Lupin Pharmaceuticals Inc, the US-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Ranbaxy slumps another 9% on FDA ban
Ranbaxy has been planning to launch couple of high-yielding generic drugs in the United States, including a version of Novartis AG's hypertension drug Diovan, with ingredients from Toansa. The FDA action could also delay the launch of a generic version of AstraZeneca Plc's blockbuster heartburn and ulcer pill Nexium in the US.
-
Ranbaxy loses investment grade on FDA ban, sinks 20%
Ambareesh Baliga of Edelweiss Global Wealth said Ranbaxy can never be a "buy" looking at the adverse news flow over the last 18 months. "Ranbaxy is a traders' stock. Traders can buy if the stock falls below Rs 300, but it can never be in core investment portfolio," he added.
-
Why Ranbaxy Laboratories shares hit a 52-week high
Ranbaxy Laboratories are at a 52-week high on Thursday at Rs 553.50 gaining over 3 per cent over the previous close. We tell you why
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
-
Lupin Launches Generic Diovan Tablets in US
Lupin Pharmaceuticals Inc, the US-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
-
Ranbaxy's Generic Version of Novartis's Blood Pressure Drug Approved by US Regulator
The US Food and Drug Administration (FDA) said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.
-
Ranbaxy slumps another 9% on FDA ban
Ranbaxy has been planning to launch couple of high-yielding generic drugs in the United States, including a version of Novartis AG's hypertension drug Diovan, with ingredients from Toansa. The FDA action could also delay the launch of a generic version of AstraZeneca Plc's blockbuster heartburn and ulcer pill Nexium in the US.
-
Ranbaxy loses investment grade on FDA ban, sinks 20%
Ambareesh Baliga of Edelweiss Global Wealth said Ranbaxy can never be a "buy" looking at the adverse news flow over the last 18 months. "Ranbaxy is a traders' stock. Traders can buy if the stock falls below Rs 300, but it can never be in core investment portfolio," he added.
-
Why Ranbaxy Laboratories shares hit a 52-week high
Ranbaxy Laboratories are at a 52-week high on Thursday at Rs 553.50 gaining over 3 per cent over the previous close. We tell you why
